VRDN Research and Charts

VRDN - Viridian Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-08-05 (Delayed quote data 2025-06-30)

Last 13.98	Change ⇓ -0.35 (-2.44%)	Volume 470,310
	Open 14.40	High 14.71	Low 13.92

8EMA (Daily) 14.54	40EMA (Daily) 14.35	50EMA (Daily) 14.35	STO (Daily) 20.168	MACD Hist (Daily) -0.324
8EMA (Weekly) 14.277	40EMA (Weekly) 15.82	50EMA (Weekly) 16.17	STO (Weekly) 72.031	MACD Hist (Weekly) 0.431


Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.